Antiarrhythmic drugs in atrial fibrillation: An overview of new agents, their mechanisms of action and potential clinical utility

Expert Opinion on Investigational Drugs

Volumn 13, Issue 7, 2004, Pages 841-855

  Choudhury, Anirban ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Antiarrhythmic agents; Atrial fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; AZIMILIDE; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENCAINIDE; ESMOLOL; FLECAINIDE; GALLOPAMIL; IBUTILIDE; LIDOCAINE; METOPROLOL; MEXILETINE; PHENYTOIN; PIBOSEROD; PILSICAINIDE; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SESAMODIL FUMARATE; SOTALOL; TECADENOSON; TEDISAMIL; UNINDEXED DRUG; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; ATRIOVENTRICULAR DISSOCIATION; BRONCHOSPASM; CLINICAL TRIAL; CORNEA DISEASE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EYE TOXICITY; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INOTROPISM; LIVER TOXICITY; LONG TERM CARE; LUNG TOXICITY; NEUROPATHY; NEUTROPENIA; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; QT PROLONGATION; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; SINUS RHYTHM; SKIN PIGMENTATION; THYROID DISEASE; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS; HUMANS; MOLECULAR MECHANISMS OF ACTION;

EID: 3543072295     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.7.841     Document Type: Review

References (98)

1. KANNEL WB, ABBOTT RD, SAVAGE DD et al.: Epidemiological features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med. (1982) 306:1018-1022.
2. BENJAMIN EJ, LEVY D, VAZIRI SM et al.: Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA (1994) 271:840-844.
3. BAILY D, LEHMANN MH, SCHUMACJER DN et al.: Hospitalization from arrhythmias in the United States: importance of atrial fibrillation. J. Am. Coll. Cardiol. (1992) 19:41A.
4. BENJAMIN EJ, WOLF PA, D'AGOSTINO RB et al.: Impact of atrial fibrillation on the risk of death: the Framingham Study. Circulation (1998) 98:946-952.
5. FREESTONE B, LIP GYH: Management of acute and recent-onset atrial fibrillation. Evidence-Based Cardiovascular Medicine (2003) 7:111-116.
6. HOHNLOSER SH, KUCH KH, LILENTHAL J: Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF) - a randomized trial. Lancet (2000) 356:1789-1794.
7. WYSE DG, WALDO AL, DIMARCO JP et al.: Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A control of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
8. VAN GELDER IC, HAGENS VE, BOSKER HA et al.: Rate control versus electrical cardioversion for persistent atrial fibrillation study group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. (2002) 347:1834-1840.
9. KUBEC G, MALOWANY L: Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Can. J. Cardiol. (1992) 8:941-946.
10. DELANGEN CDJ, VAN DEN BERG MP, HAAKSMA J et al.: Autocorrelation of AA intervals in artificially induced atrial fibrillation in the porcine heart. In: Atrial Fibrillation. Mechanisms and Therapeutic Strategies. SB Olsson, MA Allessi, RWF Campbell (Eds). Futura Publising, Co., Armonk, NY (1994):51-66.
11. WIJFFELS MC, KIRCHHOF CJ, DORLAND R et al.: Arrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation (1995) 92:1954-1968.
12. KONINGS KT, KIRCHHOF CJ, SMEETS JR et al.: High density mapping of electrically induced atrial fibrillation in humans. Circulation (1994) 89:1665-1680.
13. WALDO AL, MacLEAN WAH, COOPER TB et al.: The use of temporarily placed epicardial leads atrial wire lectrodes for the diagnosis and treatment of cardiac arrhythmias following open heart surgery. J. Thorac. Cardiovasc. Surg. (1978) 76:500-505.
14. WELLS LJ JR, KARP RB, KOUCHOUKOS NT et al.: Catheterization of atrial fibrillation in man: studies following open heart surgery. PACE (1978) 1:426-438.
15. PANDOZI C, SANTINI M: Update on atrial remodeling owing to rate; does atrial fibrillation always beget atrial fibrillation? Eur. Heart J. (2001) 22:541-553.
16. 2+-ATPase mRNA of ryanodine receptor, calsequestrin and phosphorylation: an insight into the mechanism of atrial remodelling. J. Am. Coll. Cardiol. (1999) 33:1231-1237.
17. MORILLO CA, KLEIN GJ, JONES DL et al.: Chronic rapid atrial pacing: structural, functional and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation (1995) 91:1588-1595.
18. SANFILIPPO AJ, ABASCAL VM, SHEHAN M et al.: Arrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation (1990) 82:792-797.
19. ALLESSIE MA BOYDEN PA, CAMM AJ et al.: Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 103:769-777.
20. REISINGER J, GATTERER E, HEINZE G et al.: Prospective comparison of flecainide versus sotalol for immediate cardioversion of AF. Am. J. Cardiol. (1998) 81:1450-1454.
21. BOTTO GL, POLITI A, BONINI W et al.: External cardioversion of atrial fibrillation: role of paddle position on technical efficiency and energy requirements. Heart (1999) 82:726-730.
22. TIELMAN RG, VAN GELDER IC, CRIJNS HJ et al.: Early recurrence of atrial fibrillation after electrical cardioversion: a result of atrial fibrillation-induced electrical remodeling of the atria? J. Am. Coll. Cardiol. (1998) 31:167-173.
23. BOTTO GL, BELOTTI G, CIRO A et al.: Verapamil pretreatment before electrical cardioversion of persistent atrial fibrillation: the VERAF Study. Eur. Heart J. (2001) 22:239.
24. PERDERSEN OD, BAQQER H, KOBER L et al.: Trandalapril reduces the incidence of strial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 100:376-380.
25. NAKASHIMA H, KUMAQAI K, URATA H et al.: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation (2000) 101:2612-2617.
26. MADRID AH, BUENO MG, REBOLLO JMG et al.: Use of irbesartan to maintain sinus thythin in patients with longstanding atrial fibrillation. Circulation (2002) 106:331-336.
27. AZPITARTE J, ALVARES M, BAUN O et al.: Value of single oral loading dose propafenone in converting recent onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur. Heart. J. (1997)18:1649-1654.
28. CAPUCCI A, VILLANI GO, ASCHIERI D et al.: Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multi-center study. Int. J. Cardiol. (1999) 68:187-196.
29. SUTTORP MJ, KINGMA JH, JESSURUN ER et al.: The value of class Ic antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J. Am. Coll. Cardiol. (1990)16:1722-1727.
30. SUTTORP MJ, KINGMA JH, JESSURUN ER et al.: Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am. J. Cardiol. (1989) 63:693-696.
31. THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL INVESTIGATORS: Preliminary report: effict of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. (1989) 321:406-412.
32. LINDELL P, SVENARUD P, ALBAGE A et al.: Electrical conversion of atrial fibrillation. Superior effects of biphasic transthoracic method when compared with the conventional monophasic method. Lakartidningen (2001) 98:3319-3321.
33. HOROWITZ LN, SPELMAN SR, GREENSPAN AM et al.: Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J. Am. Coll. Cardiol. (1985) 6:1402-1407.
34. TUZCU EM, GILBO J, MASTERSON M et al.: The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias. Cleve. Clin. J. Med. (1989) 56:238-242.
35. KOCHIADAKIS GE, IGOUMENDIS NE, MARKETOU ME et al.: Low dose amiodarone and sotalol in the treatment of recurrent symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart (2000) 84:251-257.
36. ROY D, TALAJIC M, DORIAN P et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N. Engl. J. Med. (2000) 342:913-920.
37. FARSHI R, KISTNER D, SARMA JSH et al.: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise. A crossover open-label study of five drug regimens. J. Am. Coll. Cardiol. (1999) 33:304-310.
38. YAMASHITA T, MURAKAWA Y, SEZAKI K et al.: Uniqueness of pilsicainide in class Ic antiarrythmics. Jpn Heart J. (1998) 39:389-397.
39. KOHNO K, TAKEUCHI Y, GOMI A et al.: Efficacy and safety of a single oral dose of pilsicainide in supraventricular arrhythmia after coronary artery bypass grafting. Jpn J. Thorac. Cardiovasc. Surg. (1998) 46(4):361-367.
40. ATARSHI H, INOQUE H, HIEJIMA K et al.: Conversion of recent onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Supression Trial on Atrial Fibrillation). The PSTAF Investigators. Am. J. Cardiol. (1996) 78:694-697.
41. KUMAGAI K, ABE H, HIRAKI T et al.: Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. Pacing Clin. Electrophysiol. (2000) 23:1880-1882.
42. KOMATSU T, NAKAMURA S, KIMURA M et al.: Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset J. Cardiol. (2001) 38:211-217.
43. OKISHIGE K, NISHIKAZI M, AZEGAMI K et al.: Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled multicenter study. Am. Heart J. (2000) 140:437-444.
44. NUMATA T, ABE H, NAGATOMO T, KOHSHI K et al.: Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. Jpn Circ. J. (2000) 64:750-754.
45. MATSUSHITA K, ISHIKAWA T, SUMITA S et al.: Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride. J. Cardiol. (2003) 42:81-86.
46. BASKIN EP, LYNCH JJ Jr: Comparative effects of increased intracellular potassium and pacing frequency on the class III activities of methanesulfonanilide Ikr blockers dofetilide, D-sotalol, E4031 and MK499. J. Cardiovasc. Pharmacol. (1994) 24:199-208.
47. FALK RH, POLLAKA, SINGH SN et al.: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J. Am. Coll. Cardiol. (1997) 29:857-865.
48. NOGAARD BL, WACHTELL K, CHRISTENSEN et al.: Efficacy and safety of intravenously administered dofetilide in acute termination of atrialfibrillation and flutter: a multicenter, randomised, double-blind, placebo-controlled trail. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart J. (1999) 137:1062-1069.
49. GREENBAUM RA, CAMPBELL TJ, CHANNER KS et al.: Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study. Circulation (1998) 98:1633.
50. SINGH S, ZOBLE RG, YELLEN L et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation (2000) 102:2385-2390.
51. BIANCOLI L, CASTRO A, DINELLI M et al.: Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, placebo-controlled study. Rur. Heart J. (2000) 21:1265-1273.
52. TROP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. N. Engl. J. Med. (1999) 34:857-865.
53. ELLENBOGEN KA, STAMBLER BS, WOOD MA et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: a dose-response study. J. Am. Coll. Cardiol. (1996) 28:130-136.
54. STAMBLER BS, WOOD MA, ELLENBOGEN KA et al.: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation (1996) 94:1613-1621.
55. STAMBLER BS, WOOD MA, ELLENBOGEN KA et al.: Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiological determinants of enhanced conversion efficacy. Circulation (1997) 96:4298-4306.
56. BERNARD E O, SCHMID ER, SCHMIDLIN D et al.: Ibutilide versus amiodarone in atrial fibrillation: A double-blinded, randomized study. Crit. Care Med. (2003) 31:1031-1034.
57. ORAL H, SOUZA J, MICHAUD GF et al.: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. NEJM (1999) 340:1849-1854.
58. STICHERLING C, OZAVDIN M, TADA H et al.: Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion. J. Cardiovasc. Pharmacol. Ther. (2002) 7:155-160.
59. KATHY GLATTER, YANFEI YANG, KANU CHATTERJEE et al.: Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation (2001) 103:253257.
60. WOOD MA, STAMBLER BS, ELLENBOGEN KA et al.: Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Am. Heart J. (1998) 135:1048-1054.
61. STAMBLER BS, BECKMAN KJ, KADISH AH et al.: Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am. J. Cardiol. (1997) 80:458-463.
62. BERGER F, BORCHARD U, HAFNER D et al.: Different inhibition patterns of tedisamil for fast and slowly activation transient outward current in rat ventricular myocytes. Naunyn-schiedeberg's Arch. Pharm. (1998) 357:291-298.
63. + currents in mammalian cardiac and glial cells. J. Pharmacol. Exp. Ther. (1990) 254:560-569.
64. + channels in adult rat ventricular cells. J. Mol. Cell. Cardiol. (1992) 24:S40.
65. DUCHOSAL F, OPIE H: KC8857, a new compound with combined bradycardic and positive inotropic effects. J. Mol. Cell. Cardiol. (1987) 19(Suppl. III) (Abstract 19).
66. FUCHS A. BUSCHMANN G, ZEIGLER D et at: Tedisamil: cardiac electrophysuiologic and functional effects in guinea pigs. Aaunyn-schiedebergs Arch. Pharm. (1989) 340:R72.
67. FOX KM, HENDERSON JR. KASKI JC et al.: Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart (2000) 83:167-171.
68. FRIEDRICHS GS, ABREU JN, DRISCOLL EM et al.: Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. J. Cardiovasc. Pharmacol, (1998) 31:56-66.
69. FISCHBACH PS, JOHNSTON PV, FRIEDRICHS GS et al: Tedisamil in a chronic canine model of atrial flutter. J. Cardiovasc. Pharmacol. (1909) 34:212-218.
70. FISCHBACH PS, BARRETT TD, GOYAL R et al: Conversion of atrial fibrillation by the experimental antiarrhythruic drug tedisamil in two canine models. J. Cardiovasc. Electrophysiol (2001) 12:1138-1144.
71. KOWEY PR, DORIAN P, BECKMANN K et al: Tedisamil for rapid conversion of recent onset atrial fibrillation and flutter to normal sinus rhythm. The North American Society of Pacing and Electrophysiology (NASPE) Washington, USA (2003) (Abstract 417).
72. + currents in isolated guinea-pig cardiomyocytes. Jpn. J. Pharmacol. (2000) 82:217.
73. NATTEL S, LIU L, ST GEORGES D: Effects of novel antiarrhythmic agent azimilide on experimental attial fibrillation and electrophysiologic properties. Cardiovasc. Res. (1998) 37:627-635.
74. CONNOLLY SJ, SCHNELL DJ, PAGE RL et al: Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am. J. Cardiol. Nov (2001) 88/9:974-979.
75. SORELLE R: ALIVE Trial. Circulation (2001) 104:E9053-E9055.
76. SINGER I, AL-KHALIDI H, NIAZI I et al.: Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J. Am. Coll. Cardiol. (2004) 43:39-43,
77. LEE JH, ROSENSHTRAUKH L, BLOSHAPKO G et at: The electrophysiologic effects of ersentilide on canine hearts. Eur. J. Pharmacol. (1995) 285:25-35.
78. Kr blocker in conscious dogs with healed myocardial infarction. Cardiovasc. Res. (1998) 40:56-63.
79. MATSUO R, SHIRAYAMA T, INOUE K et at: SD3212, a new antiarrhythmic drug raises the atrial fibrillation threshold in rabbit hearts. Heart Vessels (1999) 14:127-136.
80. HASHIMOTO H, UMEMURA K, ARAKI S et al: Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model. Biol. Pharm. Buff (1994) 17:548-550.
81. GAUTIER-P, GUILLEMARE E, MARION A et at: Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J. Cardiovasc. Pharmacol (2003) 41:191-202.
82. LALEVÉE N, BARRÈRE LEMAIRE S, GAUTIER P et al: Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J. Cardiovasc. Electrophysiol. (2003) 14:885-890.
83. SUN W, SARMA JSM, SINGH BN: Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: Comparison with amiodarone. J. Cardiovasc. Pharmacol. (2002) 39:677-684.
84. PANTOS C, MOUROUZIS 1, DELBRUYÈRE M et al. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. Eur. J. Pharmacol. (2002) 444(3):191-196.
85. TOUBOUL P, BRUGADA J, CAPUCCI A et at: Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur. Heart J. (2003) 24:1481-1487.
86. JAHNEL U, RUPP J, ERTL R et al.: Positive inotropic response to 5-HT in human atrial but not ventricular heart muscle. Naunyn Schmiedbergs Arch. Pharm. (1992) 346:482-485.
87. 4 receptors mediate arrhythmias? Trends Pharmacol. Sci. (1994) 15:451-455.
88. NATTEL S, BLASIO E, BEATCH GN et at: RSD123 5: A novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs. Eur. Heart J. (2001) 22(Suppl. 448).
89. BILLMAN GE: RSD1235. Cardiome. Curr. Opin. Investig. Drugs (2003) 4(3):352-354.
90. BEATCH GN, SHINAGAWA K, JOHNSON BD et al.: RSDI 235 selectively prolonis atrial refractoriness and terminates AF in dogs with electrically remodeled atria. S. World Congn Pharmacol (2002) 24:(Abstract 21.11).
91. BEATCH GN, SHINAGAWA K, JOHNSON BD et al: Safety and pharmacokinetics of RSD1235, a novel atrial fibrillation converting drug, in healthy volunteers. Cardiovasc. Drugs Then (2002) 16:(Suppl. 149).
92. Cardiome drug effective for heart patients. Cardiome Pharma Corp. Press Release 2002 September 2002.
93. l-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am. J. Physiol. Heart Cirr. Physiol. (2001) 280:334-343.
94. 2A-adenosine receptor activation for ATP-mediated coronary vasodilation in guinea-pig isolated heart. Br. J. Pharmacol. (2000) 130:1065-1075.
95. l adenosine receptor agonist (CVT-5 10) with diltiazem fbr slowing of AV nodal conduction in guinea-pig. Br. J. Pharmacol. (1999) 126:137-146.
96. COPLEN SE, ANTMAN EM, BERLIN JA et al: Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized controlled trials. Circulation (1990) 82:1106-1116.
97. MOSS AJ, DAVIS HT, CONARD DL et al.: Digitalis associated mortality after myocardial infarction. Circulation (1981) 64:1150-1156.
98. MITROVIC V, OEHM E, THORMANN J et al.: Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease. Clin. Cardiol (1998) 21:492-502.